• 1
    Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355365.
  • 2
    Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 12611269.
  • 3
    Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339354.
  • 4
    Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796806.
  • 5
    Canducci F, Sampaolo M, Marinozzi MC et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009; 23: 455460.
  • 6
    Malet I, Delelis O, Soulie C et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 795804.
  • 7
    Sichtig N, Sierra S, Kaiser R et al. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother 2009; 64: 2532.
  • 8
    Buzon MJ, Dalmau J, Puertas MC et al. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 2010; 24: 1725.
  • 9
    Canducci F, Marinozzi MC, Sampaolo M et al. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother 2010; 65: 42542.
  • 10
    Buzon MJ, Marfil S, Puertas MC et al. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antivir Ther 2008; 13: 881893.
  • 11
    Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83: 1144011446.
  • 12
    Fransen S, Karmochkine M, Huang W et al. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 2009; 53: 45224524.
  • 13
    Boeri E, Gianotti N, Canducci F et al. Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. AIDS Res Hum Retroviruses 2003; 19: 11511153.
  • 14
    Frost SD. Dynamics and evolution of HIV-1 during structured treatment interruptions. AIDS Rev 2002; 4: 119127.
  • 15
    Gianotti N, Galli L, Boeri E et al. In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients. New Microbiol 2005; 28: 319326.
  • 16
    Zaccarelli M, Lorenzini P, Ceccherini-Silberstein F et al. Historical resistance profile helps to predict salvage failure. Antivir Ther 2009; 14: 285291.
  • 17
    Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, Maserati R. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol 2009; 82: 116122.
  • 18
    Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20: 795803.
  • 19
    Ceccherini-Silberstein F, Malet I, D’Arrigo R et al. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11: 1729.
  • 20
    Menzo S, Monachetti A, Balotta C et al. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS 2003; 17: 663671.